8-K: Candel Therapeutics Announces Upcoming Presentations at ASCO 2024 Highlighting Promising Cancer Immunotherapies

Candel Therapeutics will present data on its CAN-3110 and CAN-2409 cancer immunotherapies at the 2024 ASCO Annual Meeting, showcasing progress in treating recurrent high-grade glioma and non-small cell lung cancer.

Summary

• Candel Therapeutics will present two poster presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
• The first presentation will feature data from the phase 1 clinical trial of CAN-3110 in patients with recurrent high-grade glioma, focusing on the feasibility and tolerability of multiple injections.
• The second presentation will show topline overall survival data from the phase 2 clinical trial of CAN-2409 plus valacyclovir in combination with immune checkpoint inhibitor treatment for non-small cell lung cancer patients who have not responded adequately to initial therapy.
• CAN-3110 is a replication-competent oncolytic virus designed to target cancer cells and activate the immune system.
• CAN-2409 is an off-the-shelf immunotherapy designed to deliver a gene to the tumor, inducing an anti-tumor immune response.

Sentiment

Score: 8

Explanation: The document presents positive clinical trial data and upcoming presentations at a major conference, indicating strong progress and potential for future success. The company has also received FDA designations, further boosting the positive sentiment.

Positives

• Multiple injections of CAN-3110 have been shown to be feasible and well-tolerated.
• CAN-2409 has demonstrated a favorable tolerability profile in over 1,000 patients.
• CAN-2409 has received Fast Track and Orphan Drug Designations from the FDA.
• The phase 1 trial of CAN-3110 showed a significant increase in median overall survival compared to historical data.
• Positive HSV-1 serology was a predictor of response and was associated with improved survival in the CAN-3110 trial.

Risks

• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• The company's ability to continue as a going concern is a risk factor.
• Final data from clinical trials may differ materially from reported interim data.

Future Outlook

The company anticipates further data from ongoing clinical trials and expects to continue advancing its development programs. The company is also evaluating the effects of multiple CAN-3110 injections in recurrent high-grade glioma.

Management Comments

• Candel is focused on developing multimodal biological immunotherapies to help patients fight cancer.

Industry Context

The announcement highlights Candel's progress in the competitive field of cancer immunotherapy, where companies are exploring novel approaches like oncolytic viruses and gene therapies to improve patient outcomes. The presentations at ASCO will provide an opportunity to compare Candel's results with other companies in the space.

Comparison to Industry Standards

• The use of oncolytic viruses like CAN-3110 is a growing area of research, with companies like Amgen (Imlygic) and Oncolytics Biotech (Pelareorep) also developing similar therapies.
• The combination of CAN-2409 with immune checkpoint inhibitors is in line with current trends in cancer treatment, where combination therapies are often used to improve efficacy.
• The reported survival data for CAN-3110, with a doubling of median overall survival compared to historical data, is a significant result and will be closely watched by the industry.
• The favorable tolerability profile of CAN-2409, with over 1,000 patients dosed, is a positive sign compared to some other immunotherapies that can have significant side effects.

Stakeholder Impact

• Shareholders may react positively to the clinical trial updates and upcoming presentations.
• Patients with recurrent high-grade glioma and non-small cell lung cancer may benefit from the development of these therapies.
• The company's employees are likely to be motivated by the progress of the clinical programs.

Next Steps

• Candel will present data at the 2024 ASCO Annual Meeting.
• Full abstracts will be released by ASCO on May 23, 2024.
• The company will continue to evaluate the effects of multiple CAN-3110 injections in recurrent high-grade glioma.
• The company will continue to advance its clinical development programs.

Key Dates

Keywords

immunotherapy, cancer, clinical trial, oncolytic virus, CAN-3110, CAN-2409, ASCO, glioblastoma, lung cancer, FDA, overall survival